0001564590-20-032977.txt : 20200722 0001564590-20-032977.hdr.sgml : 20200722 20200722071525 ACCESSION NUMBER: 0001564590-20-032977 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20200721 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200722 DATE AS OF CHANGE: 20200722 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MYRIAD GENETICS INC CENTRAL INDEX KEY: 0000899923 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 870494517 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26642 FILM NUMBER: 201040258 BUSINESS ADDRESS: STREET 1: 320 WAKARA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 BUSINESS PHONE: 801-584-3600 MAIL ADDRESS: STREET 1: 320 WAKARA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 8-K 1 mygn-8k_20200721.htm 8-K mygn-8k_20200721.htm
false 0000899923 0000899923 2020-07-21 2020-07-21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 21, 2020

 

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

0-26642

 

87-0494517

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

320 Wakara Way

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (801) 584-3600

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Public Common Stock, $0.01 par value

 

MYGN

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

ITEM 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

(b) On July 21, 2020, Walter Gilbert, Ph.D. announced that he will retire from the Board of Directors (the “Board”) of Myriad Genetics, Inc. (“Myriad”), effective as of the date of Myriad’s 2020 Annual Meeting of Stockholders.

 

(d)  On July 21, 2020, the Board approved an increase in the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D. Ph.D. to fill the newly created vacancy, effective immediately, to serve as a Class I Director with a term expiring at Myriad’s 2021 Annual Meeting of Stockholders.  The Board has determined that Dr. Skovronsky meets the independence requirements of the Securities and Exchange Commission and the Nasdaq Stock Market Rules.  The Board appointed Dr. Skovronsky to serve on the Research and Product Innovation Committee of the Board, effective immediately.

 

Dr. Skovronsky will be compensated for his service as director on the same basis as other non-employee directors of Myriad, as more fully described in the “Director Compensation” section of Myriad’s definitive proxy statement for the 2019 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on October 16, 2019.  Pursuant to Myriad’s non-employee director compensation policy, in connection with his appointment to the Board Dr. Skovronsky will be granted a restricted stock unit award for shares of Myriad’s common stock having an aggregate value of $300,000.  The foregoing grant will vest one year following the grant date.  Dr. Skovronsky will also enter into Myriad’s standard indemnification agreement for directors and executive officers.

 

There are no arrangements or understandings between Dr. Skovronsky and any other person pursuant to which he was selected to serve on the Board, and Dr. Skovronsky is not party to any related party transactions required to be reported pursuant to Item 404(a) of Regulation S-K.

 

On July 22, 2020, Myriad issued a press release announcing Dr. Skovronsky’s appointment to the Board and Dr. Gilbert’s retirement from the Board, a copy of which is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

 

 

ITEM 9.01

Financial Statements and Exhibits.

 

Exhibit

Number

 

Description

 

 

 

99.1

 

Press Release, dated July 22, 2020.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

The exhibit(s) may contain hypertext links to information on our website or other parties’ websites. The information on our website and other parties’ websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

MYRIAD GENETICS, INC.

 

 

 

 

Date:  July 22, 2020

By:

 

/s/ R. Bryan Riggsbee

 

 

 

R. Bryan Riggsbee

 

 

 

Interim President and Chief Executive Officer, Chief Financial Officer

 

 

 EX-99.1 2 mygn-ex991_43.htm EX-99.1 mygn-ex991_43.htm

Exhibit 99.1

 

News Release

 

Media Contact: Jared MaxwellInvestor Contact: Scott Gleason

  (801) 505-5027    (801) 584-1143

  jmaxwell@myriad.com    sgleason@myriad.com

 

 

Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.

 

Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriad’s Board of Directors.  Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of Directors

 

 

SALT LAKE CITY, July 22, 2020 – Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today announced the election of Daniel M. Skovronsky, M.D., Ph.D., age 47, to its Board of Directors, effective immediately, expanding the Board to ten members.  Additionally, Dr. Skovronsky was appointed to the Research and Product Innovation Committee of Myriad’s Board.

Dr. Skovronsky serves as Chief Science Officer and President of Lilly Research Laboratories at Eli Lilly and Company.  He previously served as the Founder and Chief Executive Officer of Avid Radiopharmaceuticals, Inc. which used non-invasive imaging to detect the early changes in the brain related to Alzheimer’s disease.  Dr. Skovronsky received his M.D., Ph.D. from University of Pennsylvania where he also completed sub-specialty training in neuropathology.

“We are honored to welcome Dr. Skovronsky to the Myriad Board,” said Louise Phanstiel, Chair of the Board of Myriad. “Dan brings a wealth of experience and expertise in research and development in multiple areas related to our diagnostic product development, including oncology, neuroscience, and anti-inflammatory diseases.  He will be instrumental in providing product development strategic insights in executing our global strategy for molecular diagnostics and precision medicine.”

The Company also announced today that Director, Vice Chair of the Board, Walter (Wally) Gilbert, Ph.D., will retire from the board at the Company’s Annual Meeting of Stockholders in December 2020.  Dr. Gilbert, co-founder of Myriad, has been on the board since March 1992. Dr. Gilbert received a Nobel Prize in Chemistry in 1980 for his development of a rapid DNA sequencing technology.  “I am proud that Myriad has grown to realize its founders’ dream of using tests based on genetic information to identify a patient’s predisposition to

 

2

 

disease,” said Dr. Gilbert.  “Myriad is dedicated to providing critical, life-changing information to people to help define their individual medical needs.  I have enjoyed helping the company grow over the years.  I am confident that Myriad’s important work for patients will continue.”

In commenting on Dr. Gilbert’s pending retirement, Louise Phanstiel said, “The Board owes a tremendous debt of gratitude to Wally for all of his countless contributions to the company and to the board over the years.  His relentless focus on the pursuit of scientific excellence and compassion for our patients as well as our Myriad team are qualities we all aspire to emulate.  The board, the company and I will greatly miss his wisdom, counsel and passion.  We wish Wally all the best.”

 

About Myriad Genetics

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

 

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Dr. Skovronsky providing product development strategic insights in executing the Company’s global strategy for molecular diagnostics and precision medicine; Dr. Gilbert retiring from the Company’s board at the Company’s Annual Meeting of Stockholders in December 2020; and the Company’s strategic directives under the caption "About Myriad Genetics."  These "forward-looking statements" are based on management's current expectations of future events and are subject

 

3

 

to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements.  These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int’l, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United

 

States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.  All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

###

 EX-101.SCH 3 mygn-20200721.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 mygn-20200721_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of each class Security12b Title Trading Symbol Trading Symbol Name of each exchange on which registered Security Exchange Name EX-101.PRE 5 mygn-20200721_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 mygn-8k_20200721_htm.xml IDEA: XBRL DOCUMENT 0000899923 2020-07-21 2020-07-21 false 0000899923 8-K 2020-07-21 MYRIAD GENETICS, INC. DE 0-26642 87-0494517 320 Wakara Way Salt Lake City UT 84108 801 584-3600 false false false false Public Common Stock, $0.01 par value MYGN NASDAQ false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Jul. 21, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 21, 2020
Entity Registrant Name MYRIAD GENETICS, INC.
Entity Central Index Key 0000899923
Entity Emerging Growth Company false
Entity File Number 0-26642
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 87-0494517
Entity Address, Address Line One 320 Wakara Way
Entity Address, City or Town Salt Lake City
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84108
City Area Code 801
Local Phone Number 584-3600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class Public Common Stock, $0.01 par value
Trading Symbol MYGN
Name of each exchange on which registered NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports mygn-8k_20200721.htm mygn-20200721.xsd mygn-20200721_lab.xml mygn-20200721_pre.xml mygn-ex991_43.htm http://xbrl.sec.gov/dei/2019-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mygn-8k_20200721.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "mygn-8k_20200721.htm" ] }, "labelLink": { "local": [ "mygn-20200721_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mygn-20200721_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mygn-20200721.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mygn", "nsuri": "http://www.myriad.com/20200721", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mygn-8k_20200721.htm", "contextRef": "C_0000899923_20200721_20200721", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "mygn-8k_20200721.htm", "contextRef": "C_0000899923_20200721_20200721", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "verboseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myriad.com/20200721/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001564590-20-032977-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-032977-xbrl.zip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end